{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:18:31Z","timestamp":1791584311619,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jhep.2016.07.020","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T10:45:01Z","timestamp":1469529901000},"page":"1140-1147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":340,"title":["Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study"],"prefix":"10.1016","volume":"65","author":[{"given":"Jorge A.","family":"Marrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Long","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois H.","family":"Geschwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Ladr\u00f3n","family":"de Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Papandreou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadatoshi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Heldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lencioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.07.020_b0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2016.07.020_b0010","first-page":"492","article-title":"Hepatocellular carcinoma: the rising tide from east to west\u2014review of epidemiology, screening and tumor markers","volume":"2","author":"Monsour","year":"2013","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.020_b0015","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.cgh.2015.08.014","article-title":"Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice","volume":"13","author":"Singal","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.020_b0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001199.pub2","article-title":"Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma","author":"Samuel","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2016.07.020_b0025","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.3748\/wjg.v21.i28.8478","article-title":"Current and future treatments for hepatocellular carcinoma","volume":"21","author":"Schlachterman","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.07.020_b0030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.020_b0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0040","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.020_b0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MEG.0b013e328333df23","article-title":"Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma","volume":"22","author":"Peck-Radosavljevic","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.020_b0050","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1742-1241.2010.02414.x","article-title":"Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study","volume":"64","author":"Lencioni","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jhep.2016.07.020_b0055","unstructured":"European Medicines Agency. EUDRALEX: The rules governing medicinal products in the European Union. Available from: http:\/\/ec.europa.eu\/enterprise\/newsroom\/cf\/itemdetail.cfm?&item_id=897. Accessed 5 November 2015."},{"key":"10.1016\/j.jhep.2016.07.020_b0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2016.07.020_b0065","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/MEG.0b013e3283386053","article-title":"Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib","volume":"22","author":"Ozenne","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.020_b0070","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1365-2036.2011.04860.x","article-title":"Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score","volume":"34","author":"Hollebecque","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.07.020_b0075","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00280-011-1616-x","article-title":"Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function","volume":"68","author":"Kim","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2016.07.020_b0080","first-page":"259","article-title":"Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction","volume":"6","author":"Al-Rajabi","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0085","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/mco.2015.536","article-title":"Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma","volume":"3","author":"da Fonseca","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0090","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","article-title":"Management of sorafenib-related adverse events: a clinician\u2019s perspective","volume":"41","author":"Brose","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0095","first-page":"40","article-title":"Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A vs. B cirrhosis","volume":"4","author":"Abou-Alfa","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.020_b0100","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0105","doi-asserted-by":"crossref","first-page":"abs2580","DOI":"10.1200\/jco.2011.29.15_suppl.2580","article-title":"Effect of hepatic impairment on sorafenib pharmacokinetics: results of a multicenter, open-label, single-dose, phase I trial","volume":"29","author":"Lettieri","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0110","unstructured":"Mitchell DY, Prins K, Ploeger B, Grevel J, Lettieri J, Meinhardt G, et al. Impact of Child-Pugh status (A, B, or C) and duration of treatment on sorafenib exposure in patients with advanced hepatocellular carcinoma in the Phase IV HATT trial: a population pharmacokinetic analysis (abstract O-030). International Liver Cancer Association, Kyoto, Japan, 5\u20137 September, 2014."},{"key":"10.1016\/j.jhep.2016.07.020_b0115","unstructured":"Bayer Pharma AG. Nexavar\u00ae (sorafenib). Summary of product characteristics. Available from: http:\/\/www.nexavar.com\/scripts\/pages\/en\/home\/\/pdf\/Nexavar_SmPC_June_2014.pdf. Accessed 5 November 2015."},{"key":"10.1016\/j.jhep.2016.07.020_b0120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mds343","article-title":"Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis","volume":"24","author":"Pressiani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0125","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1093\/annonc\/mdt055","article-title":"Sorafenib: from literature to clinical practice","volume":"24","author":"Di Marco","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0130","doi-asserted-by":"crossref","first-page":"abs4083","DOI":"10.1200\/jco.2011.29.15_suppl.4083","article-title":"The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis","volume":"29","author":"Chiu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1001-9294(14)60017-1","article-title":"Sorafenib in liver function impaired advanced hepatocellular carcinoma","volume":"29","author":"Ji","year":"2014","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.jhep.2016.07.020_b0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach \u2013 the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.07.020_b0145","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991.x","article-title":"Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib","volume":"42","author":"Otsuka","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2016.07.020_b0150","doi-asserted-by":"crossref","first-page":"837","DOI":"10.5414\/CP201907","article-title":"Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib","volume":"51","author":"Shin","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.07.020_b0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4254\/wjh.v6.i9.670","article-title":"Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma","volume":"6","author":"Shomura","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.020_b0160","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/hep.25637","article-title":"Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma","volume":"56","author":"Bettinger","year":"2012","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816303464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816303464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T18:22:09Z","timestamp":1568226129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816303464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0168827816303464"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}